{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:43:09Z","timestamp":1790685789552,"version":"4.1.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Accumulating evidence suggests that autoreactive plasma cells play an important role in systemic lupus erythematosus (SLE). In addition, several proinflammatory cytokines promote autoreactive B cell maturation and autoantibody production. Hence, therapeutic targeting of such cytokine pathways using a selective JAK2 inhibitor, CEP-33779 (JAK2 enzyme IC50 = 1.3 nM; JAK3 enzyme IC50\/JAK2 enzyme IC50 = 65-fold), was tested in two mouse models of SLE. Age-matched, MRL\/lpr or BWF1 mice with established SLE or lupus nephritis, respectively, were treated orally with CEP-33779 at 30 mg\/kg (MRL\/lpr), 55 mg\/kg or 100 mg\/kg (MRL\/lpr and BWF1). Studies included reference standard, dexamethasone (1.5 mg\/kg; MRL\/lpr), and cyclophosphamide (50 mg\/kg; MRL\/lpr and BWF1). Treatment with CEP-33779 extended survival and reduced splenomegaly\/lymphomegaly. Several serum cytokines were significantly decreased upon treatment including IL-12, IL-17A, IFN-\u03b1, IL-1\u03b2, and TNF-\u03b1. Anti-nuclear Abs and frequencies of autoantigen-specific, Ab-secreting cells declined upon CEP-33779 treatment. Increased serum complement levels were associated with reduced renal JAK2 activity, histopathology, and spleen CD138+ plasma cells. The selective JAK2 inhibitor CEP-33779 was able to mitigate several immune parameters associated with SLE advancement, including the protection and treatment of mice with lupus nephritis. These data support the possibility of using potent, orally active, small-molecule inhibitors of JAK2 to treat the debilitative disease SLE.<\/jats:p>","DOI":"10.4049\/jimmunol.1101228","type":"journal-article","created":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T11:41:52Z","timestamp":1314877312000},"page":"3840-3853","source":"Crossref","is-referenced-by-count":69,"title":["Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2"],"prefix":"10.1093","volume":"187","author":[{"given":"Lily D","family":"Lu","sequence":"first","affiliation":[{"name":"Cephalon, Inc., Worldwide Discovery Research , West Chester, PA 19380"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine L","family":"Stump","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Worldwide Discovery Research , West Chester, PA 19380"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nate H","family":"Wallace","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Worldwide Discovery Research , West Chester, PA 19380"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Dobrzanski","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Worldwide Discovery Research , West Chester, PA 19380"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Serdikoff","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Worldwide Discovery Research , West Chester, PA 19380"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane E","family":"Gingrich","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Worldwide Discovery Research , West Chester, PA 19380"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J","family":"Dugan","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Worldwide Discovery Research , West Chester, PA 19380"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thelma S","family":"Angeles","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Worldwide Discovery Research , West Chester, PA 19380"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S","family":"Albom","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Worldwide Discovery Research , West Chester, PA 19380"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L","family":"Mason","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Worldwide Discovery Research , West Chester, PA 19380"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Ator","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Worldwide Discovery Research , West Chester, PA 19380"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D","family":"Dorsey","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Worldwide Discovery Research , West Chester, PA 19380"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Worldwide Discovery Research , West Chester, PA 19380"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M","family":"Seavey","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Worldwide Discovery Research , West Chester, PA 19380"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,10,1]]},"reference":[{"key":"2025032410374783700_r1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(06)92001-X","article-title":"Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease","volume":"92","author":"Fairhurst","year":"2006","journal-title":"Adv. Immunol."},{"key":"2025032410374783700_r2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrrheum.2010.63","article-title":"Genetics of SLE: evidence from mouse models","volume":"6","author":"Morel","journal-title":"Nat. Rev. Rheumatol."},{"key":"2025032410374783700_r3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1191\/0961203303lu1024oa","article-title":"Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention","volume":"13","author":"Aringer","year":"2004","journal-title":"Lupus"},{"key":"2025032410374783700_r4","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1084\/jem.20070850","article-title":"A role for sex chromosome complement in the female bias in autoimmune disease","volume":"205","author":"Smith-Bouvier","year":"2008","journal-title":"J. Exp. Med."},{"key":"2025032410374783700_r5","first-page":"419","article-title":"A new hypothesis of the possible mechanisms of gender differences in systemic lupus erythematosus","volume":"28","author":"Sekigawa","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"2025032410374783700_r6","doi-asserted-by":"crossref","first-page":"A277","DOI":"10.1016\/j.autrev.2009.12.008","article-title":"The geoepidemiology of systemic lupus erythematosus","volume":"9","author":"Borchers","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"2025032410374783700_r7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10875-007-9104-0","article-title":"Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus","volume":"27","author":"Chun","year":"2007","journal-title":"J. Clin. Immunol."},{"key":"2025032410374783700_r8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2249.2008.03758.x","article-title":"Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis","volume":"154","author":"Tucci","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"2025032410374783700_r9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.gene.6364408","article-title":"High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus","volume":"8","author":"Niewold","year":"2007","journal-title":"Genes Immun."},{"key":"2025032410374783700_r10","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood-2009-12-259457","article-title":"Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow","volume":"116","author":"Winter","year":"2010","journal-title":"Blood"},{"key":"2025032410374783700_r11","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.3899\/jrheum.100170","article-title":"Interleukin 6 gene polymorphisms are associated with systemic lupus erythematosus in Koreans","volume":"37","author":"Jeon","year":"2010","journal-title":"J. Rheumatol."},{"key":"2025032410374783700_r12","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/ard.2004.022681","article-title":"Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia","volume":"64","author":"Ripley","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"2025032410374783700_r13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3899\/jrheum.090194","article-title":"Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus","volume":"37","author":"Cash","year":"2010","journal-title":"J. Rheumatol."},{"key":"2025032410374783700_r14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1196\/annals.1313.014","article-title":"Long-lived plasma cells and their contribution to autoimmunity","volume":"1050","author":"Hoyer","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2025032410374783700_r15","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1189\/jlb.0410217","article-title":"gp130 at the nexus of inflammation, autoimmunity, and cancer","volume":"88","author":"Silver","year":"2010","journal-title":"J. Leukoc. Biol."},{"key":"2025032410374783700_r16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/intimm\/dxh030","article-title":"Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases","volume":"16","author":"Fujimoto","year":"2004","journal-title":"Int. Immunol."},{"key":"2025032410374783700_r17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000066856","article-title":"Signaling mutations and autoimmunity","volume":"6","author":"Yu","year":"2003","journal-title":"Curr. Dir. Autoimmun."},{"key":"2025032410374783700_r18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/ncprheum0896","article-title":"Update on the management of lupus nephritis: let the treatment fit the patient","volume":"4","author":"Bertsias","year":"2008","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"2025032410374783700_r19","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2010050472","article-title":"Updates on the treatment of lupus nephritis","volume":"21","author":"Bomback","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"2025032410374783700_r20","first-page":"1256","article-title":"Novel treatments for systemic lupus erythematosus","volume":"11","author":"Gayed","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"2025032410374783700_r21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/11535420-000000000-00000","article-title":"B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data","volume":"70","author":"Looney","year":"2010","journal-title":"Drugs"},{"key":"2025032410374783700_r22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s00393-008-0427-x","article-title":"[Depletion of plasma cells - a novel strategy in the therapy of systemic lupus erythematosus in mice and man]","volume":"68","author":"Voll","year":"2009","journal-title":"Z. Rheumatol."},{"key":"2025032410374783700_r23","volume-title":"Preparation and Uses of 1,2,4-Triazolo [1,5A] Pyridine Derivatives.","author":"Matthew","year":"2010"},{"key":"2025032410374783700_r24","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/ar3329","article-title":"A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis","volume":"13","author":"Stump","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"2025032410374783700_r25","doi-asserted-by":"crossref","first-page":"5.60.1","DOI":"10.1002\/0471141755.ph0560s53","article-title":"Animal models of systemic lupus erythematosus (SLE) and ex vivo assay design for drug discovery (unit 14)","volume":"53","author":"Seavey","year":"2011","journal-title":"Curr. Protoc. Pharmacol."},{"key":"2025032410374783700_r26","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat. Med."},{"key":"2025032410374783700_r27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clim.2006.09.009","article-title":"A female preponderance for chemically induced lupus in SJL\/J mice","volume":"122","author":"Smith","year":"2007","journal-title":"Clin. Immunol."},{"key":"2025032410374783700_r28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2172-11-55","article-title":"Novel method of monitoring trace cytokines and activated STAT molecules in the paws of arthritic mice using multiplex bead technology","volume":"11","author":"Lu","year":"2010","journal-title":"BMC Immunol."},{"key":"2025032410374783700_r29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum."},{"key":"2025032410374783700_r30","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/ard.2007.085688","article-title":"Analysis of C1q polymorphisms suggests association with systemic lupus erythematosus, serum C1q and CH50 levels and disease severity","volume":"68","author":"Martens","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"2025032410374783700_r31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.autrev.2010.02.003","article-title":"Pathways: strategies for susceptibility genes in SLE","volume":"9","author":"Kelley","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"2025032410374783700_r32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/jcp.53.6.424","article-title":"The use of laboratory tests in the diagnosis of SLE","volume":"53","author":"Egner","year":"2000","journal-title":"J. Clin. Pathol."},{"key":"2025032410374783700_r33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/08916930903002446","article-title":"Anti-nuscleosome antibody, a reliable indicator for lupus nephritis","volume":"42","author":"Kiss","year":"2009","journal-title":"Autoimmunity"},{"key":"2025032410374783700_r34","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.4049\/jimmunol.165.10.5970","article-title":"Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus","volume":"165","author":"Odendahl","year":"2000","journal-title":"J. Immunol."},{"key":"2025032410374783700_r35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nri1572","article-title":"Regulation of plasma-cell development","volume":"5","author":"Shapiro-Shelef","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"2025032410374783700_r36","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/intimm\/dxm051","article-title":"The effects of microenvironment and internal programming on plasma cell survival","volume":"19","author":"Minges Wols","year":"2007","journal-title":"Int. Immunol."},{"key":"2025032410374783700_r37","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.mehy.2009.03.050","article-title":"Will Jill come tumbling after? The case for a JAK2-type mutation as a prequel to the connective tissue disorders","volume":"73","author":"McQueen","year":"2009","journal-title":"Med. Hypotheses"},{"key":"2025032410374783700_r38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/03009740701606010","article-title":"Constitutive STAT3 activation in peripheral CD3(+) cells from patients with primary Sj\u00f6gren\u2019s syndrome","volume":"37","author":"Ramos","year":"2008","journal-title":"Scand. J. Rheumatol."},{"key":"2025032410374783700_r39","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0961203310367660","article-title":"Jak\/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL\/lpr mice","volume":"19","author":"Wang","year":"2010","journal-title":"Lupus"},{"key":"2025032410374783700_r40","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1159\/000108102","article-title":"Inhibition of Jak\/STAT signaling ameliorates mice experimental nephrotic syndrome","volume":"27","author":"Li","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"2025032410374783700_r41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1593\/neo.91192","article-title":"INCB16562, a JAK1\/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support","volume":"12","author":"Li","year":"2010","journal-title":"Neoplasia"},{"key":"2025032410374783700_r42","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050","volume":"184","author":"Fridman","year":"2010","journal-title":"J. Immunol."},{"key":"2025032410374783700_r43","first-page":"394","article-title":"Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis","volume":"13","author":"Mesa","year":"2010","journal-title":"IDrugs"},{"key":"2025032410374783700_r44","first-page":"491","article-title":"CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders","volume":"10","author":"West","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"2025032410374783700_r45","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1182\/blood-2007-04-083402","article-title":"Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2\/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders","volume":"111","author":"Hexner","year":"2008","journal-title":"Blood"},{"key":"2025032410374783700_r46","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/clpt.2010.1","article-title":"Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases?","volume":"87","author":"Febbraio","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"2025032410374783700_r47","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum."},{"key":"2025032410374783700_r48","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-065X.2010.00945.x","article-title":"B-cell targeted therapies in human autoimmune diseases: an updated perspective","volume":"237","author":"Townsend","year":"2010","journal-title":"Immunol. Rev."},{"key":"2025032410374783700_r49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"2025032410374783700_r50","doi-asserted-by":"crossref","first-page":"R112","DOI":"10.1186\/ar2510","article-title":"Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients","volume":"10","author":"Fu","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"2025032410374783700_r51","first-page":"927","article-title":"Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice","volume":"144","author":"Ryffel","year":"1994","journal-title":"Am. J. Pathol."},{"key":"2025032410374783700_r52","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/0961203310371161","article-title":"The interferon-alpha signature of systemic lupus erythematosus","volume":"19","author":"Obermoser","year":"2010","journal-title":"Lupus"},{"key":"2025032410374783700_r53","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jama.1966.03100040091025","article-title":"NZB\/NZW mice as a model of systemic lupus erythematosus","volume":"195","author":"Dubois","year":"1966","journal-title":"JAMA"},{"key":"2025032410374783700_r54","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri1886","article-title":"Competence and competition: the challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"2025032410374783700_r55","doi-asserted-by":"crossref","first-page":"e17739","DOI":"10.1371\/journal.pone.0017739","article-title":"IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation","volume":"6","author":"Eto","year":"2011","journal-title":"PLoS ONE"},{"key":"2025032410374783700_r56","doi-asserted-by":"crossref","first-page":"607084","DOI":"10.1155\/2010\/607084","article-title":"Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches","volume":"2010","author":"L\u00f3pez-Pedrera","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"2025032410374783700_r57","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S0891-5849(01)00649-9","article-title":"Activation of JAK2 by the oxidative stress generated with oxidized low-density lipoprotein","volume":"31","author":"Mazi\u00e8re","year":"2001","journal-title":"Free Radic. Biol. Med."},{"key":"2025032410374783700_r58","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1191\/096120301717164994","article-title":"Prolactin in human systemic lupus erythematosus","volume":"10","author":"Jara","year":"2001","journal-title":"Lupus"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/187\/7\/3840\/61583709\/1101228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/187\/7\/3840\/61583709\/1101228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:31:43Z","timestamp":1743136303000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/187\/7\/3840\/7976531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,1]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,10,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1101228","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,10]]},"published":{"date-parts":[[2011,10,1]]}}}